Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a ...
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...
Discover how poor sleep quality significantly increases malnutrition risk in adolescents with cystic fibrosis. Learn why ...
Credit: Vertex. According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment. An additional 94 non-F508del CFTR mutations and a boxed ...
Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...
Clinical Updates in Cystic Fibrosis-Related Diabetes Learn more about cystic fibrosis-related diabetes, the commonest extrapulmonary complication of cystic fibrosis. Seminars in Respiratory and ...
Medical Xpress on MSN12d
New animal model offers insights into pancreatic disease and diabetesCystic fibrosis (CF) is a life-threatening genetic disease affecting ... endocrine dysfunction—manifested as CFRD—presents ...
Boehringer Ingelheim (BI) and the UK Cystic Fibrosis Gene Therapy Consortium ... Ingelheim’s capabilities in drug discovery and the clinical development of novel breakthrough therapeutic agents.” ...
FDA 2025 pulmonology drug alerts, including drug approvals/warnings, vaccine approvals, and medical device recalls/updates.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback